Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Share News (HAYD)

Share Price Information for Haydale (HAYD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.345
Bid: 0.34
Ask: 0.35
Change: 0.00 (0.00%)
Spread: 0.01 (2.941%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.345
HAYD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half

Thu, 26th Oct 2023 18:12

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Wednesday and Thursday, and not separately reported by Alliance News:

----------

Riverstone Credit Opportunities Income PLC - London-based energy infrastructure and energy transition credit investor - Net asset value at September 30 was USD1.07, unchanged from June 30. Says this stability was due to continued strong portfolio performance during the third quarter of 2023, and that as of September 30 it is nearly fully invested based on the revolving credit facility added in the fourth quarter last year and on current portfolio commitments. Riverstone Credit says it remains extremely well positioned due to its portfolio of accredited energy-transition focused investments through green or sustainability-linked structured loans. Notes "backdrop of strong energy market performance, the global focus on decarbonisation and the company's unique focus on short duration lending."

----------

Bloomsbury Publishing PLC - London-based publisher - Pretax profit for the half year ended August 31 was up 8% to GBP14.0 million from GBP12.9 million the year before. Says revenue increased 11% to GBP136.7 million from GBP122.9 million, and diluted earnings per share rose 11% to 13.66 pence from 12.30p. Consumer revenue grew 17% to GBP89.4 million, Adult Trade revenue rose 8% to GBP27.6 million and Children's Trade revenue grew 22% to GBP61.7 million. Declares interim dividend of 3.70p per share, more than double 1.41p the prior year. Cash at August 31 totalled GBP39.1 million, down from GBP41.5 million on the same day in 2022. Says it is confident it will achieve market expectations for the year ending February 29 2024, meaning revenue of GBP273.1 million and profit before tax and "highlighted items" of GBP32.5 million.

----------

Schroder Income Growth Fund PLC - UK-based investment company - Lifts dividend for the year ended August 31 by 4.6% to 13.80p per share from 13.20p the year before. Net asset value total return was positive 4.2%, underperforming against positive 5.2% from the FTSE All Share Total Return index. NAV per share decreased to 293.58p from 295.26p. Says many challenges "look set to continue into the year ahead."

----------

Haydale Graphene Industries PLC - Carmarthenshire, Wales-based technology solutions company - Pretax loss for the year ended June 30 widens to GBP6.6 million compared with GBP5.2 million the previous year. Revenue increased 48% to GBP4.3 million from GBP2.9 million, with US sales continuing to progress on "growth in the core aerospace and automotive markets". Administrative expenses increased 13% to GBP6.3 million from GBP5.5 million. Non-Executive Chair David Banks says: "We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations...the board remains confident that the company will be able to take advantage of the traction it is now seeing."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that in six months ended July 31, pretax loss widened to GBP6.6 million from GBP4.5 million the previous year. Revenue fell 46% to GBP160,000 from GBP295,000. Chief Executive Officer Ali Mortazavi says: "Despite a severe macroeconomic climate, we have made significant progress during the past six months...we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor." Research & development expenditure increased to GBP5.3 million from GBP3.1 million. Company expects higher "underlying cash burn" in the current half year due to its "planned increase in R&D spend to continue the expansion of our AI capabilities and progress the identification and execution of preclinical targets, together with sustaining our active IP strategy as novel inventions are generated."

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Feb 2015 09:22

Haydale Graphene Inks Deals With Swansea, Alex Thomson Racing

Read more
3 Nov 2014 07:46

Haydale Graphene To Buy Development Partner EPL For GBP1.4 Million

Read more
23 Oct 2014 08:52

Haydale Graphene Orders More Plasma Reactors From Tantec

Read more
30 Sep 2014 14:13

Haydale Graphene Expects Revenue Increase In Coming Year

Read more
4 Aug 2014 07:54

Haydale Graphene In Marketing Agreement For Asia-Pacific

Read more
21 Jul 2014 09:07

Haydale Graphene Industries Signs Marketing, Distribution Deal

Read more
17 Jul 2014 11:56

Haydale Graphene Enters New Consulting Agreement

Read more
11 Jul 2014 14:38

Haydale Graphen to collaborate with WCPC

Technology group Haydale Graphene has partnered with WCPC to produce graphene-based inks in an effort to strengthen its product portfolio. WCPC, an R&D centre for printing and coating processes, is expected to develop and refine commercial ink formulations supplied by Haydale. The Swansea Univers

Read more
11 Jul 2014 08:19

Haydale Graphene Inks Research Agreement With Swansea University

Read more
22 May 2014 15:57

Jupiter finance chief reduces stake amid controversy at AGM

Jupiter Fund Management's Chief Financial Officer, Philip Johnson, traded in 63,588 shares, making only a small dent in his holding, which was reduced to 1.32m. Johnson, who took up the role in 2009, paid 383.80p per share, giving the deal a trade value of £244,051. The purchase was made the day

Read more
8 May 2014 12:23

UK WINNERS & LOSERS: Standard Chartered, Barclays Lead FTSE 100 Risers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Barclays, up 4.9%. Barclays has detailed plans to shrink its investment bank with a new round

Read more
8 May 2014 09:15

Hume Capital Plummets As Board Reviews Financial Resources, CEO Departs

LONDON (Alliance News) - Hume Capital Securities PLC plummeted to the bottom of the AIM All-Share market Thursday after the firm announced the resignation of Chief Executive Nitin Parekh amid a board review of its financial resources. The firm said it has appointed Jonathan Freeman, a non-e

Read more
29 Apr 2014 08:56

Haydale Graphene: Not Planning Legal Action Against Hume Capital

LONDON (Alliance News) - Haydale Graphene Industries PLC Tuesday said its directors have "no current intention" of pursuing any legal action against its broker, Hume Capital Securities PLC. Haydale moved to distance itself from press reports suggesting it was gearing up to take the legal ro

Read more
22 Apr 2014 12:09

UK MIDDAY BRIEFING: Drug Stocks Soar, Led By Glaxo And AstraZeneca

LONDON (Alliance News) - Pharmaceutical stocks are reigning over the first session following the long Easter bank holiday, with mergers and acquisitions leading investor interest.

GlaxoSmithKline has signed a three-part inter-conditional transaction with Swiss healt

Read more
22 Apr 2014 10:58

UK WINNERS & LOSERS: Pharmaceutical Companies Jump On M&A News

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Tuesday.
-------
FTSE 100 - WINNERS
-------
AstraZeneca, up 7.1%. The pharmaceutical company has jumped after The Sunday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.